What are the recommended laser parameters—including wavelength, spot size, pulse duration, power titration, and technique—for focal retinal photocoagulation of isolated microaneurysms and larger focal lesions?

Recommended Laser Settings for Focal Retinal Photocoagulation

For focal treatment of isolated microaneurysms in diabetic macular edema, use a 50-60 μm spot size, 0.05-0.1 second (50-100 ms) pulse duration, green to yellow wavelength (532 nm preferred), with power titrated to achieve either visible color change of the microaneurysm or a mild gray-white burn beneath it. 1

Core Laser Parameters

Wavelength Selection

• Green wavelength (532 nm) is the standard recommendation for focal photocoagulation of microaneurysms 1
• Yellow wavelengths are also acceptable alternatives 1
• Green wavelength produces greater burn intensity and lesion size compared to red wavelengths at equivalent parameters, making it more effective for targeting small focal lesions 2

Spot Size

• Use 50-60 μm spot size for direct treatment of microaneurysms 1
• This smaller spot size allows precise targeting of individual microaneurysms while minimizing collateral damage 1
• Larger spot sizes (100 μm) result in smaller lesion intensity for the same power, making them less suitable for focal microaneurysm treatment 2

Pulse Duration

• Apply 0.05-0.1 second (50-100 millisecond) duration 1
• Shorter pulse durations (50 ms) significantly reduce patient pain and decrease total surgery duration compared to longer exposures 2
• The 50-100 ms range provides adequate thermal effect while maintaining patient comfort 2

Power Titration and Treatment Endpoint

Power Adjustment Technique

• Begin with test burns to establish appropriate power levels before treating actual microaneurysms 1
• Titrate power upward until achieving the desired clinical endpoint 1
• Power requirements typically range from 100-150 mW for standard parameters, but must be individualized based on media clarity, pigmentation, and real-time burn appearance 2

Clinical Endpoint

• The treatment endpoint is either: 1
  • Visible color change of the microaneurysm itself, OR
  • A mild gray-white burn evident beneath the microaneurysm
• Avoid creating intense white burns, which indicate excessive treatment and increase risk of scotoma formation 1

Treatment Technique and Targeting

Anatomic Treatment Zones

• Direct laser to all microaneurysms in areas of retinal thickening between 500-3000 μm from the macular center 1
• For persistent center-involved edema after initial laser session, microaneurysms between 300-500 μm from center may be treated, but generally avoid this zone if visual acuity is better than 20/40 1, 3
• Never treat within 500 μm of the foveal center with conventional focal laser to prevent permanent central scotomas 1, 3

Precision Considerations

• Modern navigated laser systems achieve 92% accuracy in hitting targeted microaneurysms compared to 72% with standard manual technique 4
• When using manual technique, careful pre-planning with fluorescein angiography overlay improves targeting accuracy 4
• The actual laser burn should overlap the targeted microaneurysm to be considered successful treatment 4

Alternative Approaches for Larger Focal Lesions

For Lesions Requiring Broader Treatment

• When treating larger focal areas of leakage (not discrete microaneurysms), the same 50-60 μm spot size and 0.05-0.1 second duration apply 1
• Maintain at least 2 burn widths separation between adjacent spots to avoid confluent scarring 1
• Use the same mild gray-white burn endpoint rather than intense white burns 1

Critical Safety Considerations

Common Pitfalls to Avoid

• Avoid excessive power that creates intense white burns, which increase risk of retinal scarring, scotoma formation, and choroidal neovascularization 1
• Do not treat microaneurysms within 500 μm of the foveal center unless using subthreshold techniques, as conventional burns in this zone cause permanent central vision loss 1, 3
• Ensure adequate time (≥13 weeks) has elapsed since prior focal laser before retreatment to allow assessment of initial treatment response 1, 3
• Recognize that focal laser is now typically deferred or used adjunctively with anti-VEGF therapy rather than as first-line monotherapy for center-involved diabetic macular edema 3

Modern Context

• Current treatment paradigms prioritize anti-VEGF injections over focal laser for center-involved diabetic macular edema, with laser serving as adjunctive therapy 3
• Approximately 40-51% of eyes achieve treatment success (visual acuity ≥20/20 or OCT central subfield <250 μm) with anti-VEGF therapy within 16 weeks 3
• Focal laser remains valuable for treating isolated microaneurysms in non-center-involved edema or as adjunctive therapy to reduce anti-VEGF treatment burden 1, 3